Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744343 | 1.00 | NR1H2 (0.32) | NR1H2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20239958 | 1.00 | NR1H2 (0.32) | NR1H2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL8510292 | 1.00 | NR1H2 (0.32) | NR1H2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL11889446 | 1.00 | NR1H2 (0.32) | NR1H2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL322583 | 0.85 | — | — | |
| SCHEMBL2744355 | 0.81 | DPP4 (0.38) | — | |
| SCHEMBL3395683 | 0.81 | DPP4 (0.38) | — | |
| SCHEMBL6757493 | 0.81 | DPP4 (0.38) | — | |
| SCHEMBL904004 | 0.79 | NR1H2 (0.57) | NR1H2 | |
| SCHEMBL20567011 | 0.79 | NR1H2 (0.57) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083907-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2024-03-14 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| EP-3630744-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-01-25 | — | — | EP | disclosed |
| CN-114591321-A | Aza-and-cyclic compounds, method for the production thereof and use thereof | 广州费米子科技有限责任公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2021-02-25 | — | — | US | disclosed |
| US-10927105-B1 | Pyrazole MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3630744-A1 | PYRAZOLE MAGL INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-106795111-B | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta [ C ] pyrroles as negative allosteric modulators of NR2B | 科登特治疗公司 | 2020-04-07 | — | — | CN | disclosed |
| CN-110678456-A | Pyrazole MAGL inhibitors | 隆德贝克拉荷亚研究中心有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-10266497-B2 | Pyrazole MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2018217805-A1 | PYRAZOLE MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180339970-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-11-29 | — | — | US | disclosed |
| US-8865738-B2 | 5-membered heterocyclic compound cyclopenta[C]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2014-10-21 | — | — | US | disclosed |
| US-20120136026-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339970-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | NR1H2 355/4885CHRNB2 3972/4885CHRNB4 4068/4885 |
| US-20240083907-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | NR1H2 455/4885CHRNB2 21/4885CHRNB4 18/4885 |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | NR1H2 355/4885CHRNB2 3972/4885CHRNB4 4068/4885 |
| US-10266497-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | NR1H2 355/4885CHRNB2 3972/4885CHRNB4 4068/4885 |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | NR1H2 355/4885CHRNB2 3972/4885CHRNB4 4068/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | NR1H2 423/4885CHRNB2 4023/4885CHRNB4 4074/4885 |
| US-10927105-B1 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | NR1H2 355/4885CHRNB2 3972/4885CHRNB4 4068/4885 |
| US-20120136026-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CA9, SCN9A, CCR9 | NR1H2 1782/4885CHRNB2 2164/4885CHRNB4 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.